Target Price | HKD29.42 |
Price | HKD19.94 |
Potential |
47.52%
register free of charge
|
Number of Estimates | 25 |
25 Analysts have issued a price target WuXi Biologics 2026 .
The average WuXi Biologics target price is HKD29.42.
This is
47.52%
register free of charge
HKD44.37
122.53%
register free of charge
HKD19.49
2.27%
register free of charge
|
|
A rating was issued by 30 analysts: 20 Analysts recommend WuXi Biologics to buy, 10 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the WuXi Biologics stock has an average upside potential 2026 of
47.52%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Billion HKD | 20.25 | 22.58 |
7.57% | 11.52% | |
EBITDA Margin | 33.44% | 35.49% |
7.10% | 6.14% | |
Net Margin | 18.05% | 18.96% |
8.07% | 5.06% |
29 Analysts have issued a sales forecast WuXi Biologics 2025 . The average WuXi Biologics sales estimate is
This results in the following potential growth metrics:
21 Analysts have issued an WuXi Biologics EBITDA forecast 2025. The average WuXi Biologics EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
27 WuXi Biologics Analysts have issued a net profit forecast 2025. The average WuXi Biologics net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share HKD | 0.89 | 1.04 |
1.11% | 16.85% | |
P/E | 19.12 | |
EV/Sales | 3.53 |
27 Analysts have issued a WuXi Biologics forecast for earnings per share. The average WuXi Biologics EPS is
This results in the following potential growth metrics and future valuations:
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.